{"DataElement":{"publicId":"4132155","version":"2","preferredName":"Melphalan Dose Clinical Trial Protocol Modification Yes No Unable to Assess Indicator","preferredDefinition":"information related to the change, addition, or omission, as part of the action plan for a clinical trial, in the administered amount of melphalan, an orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity that alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.:The preferred value domain to indicate a question with permissible values of yes/no/unable to assess.","longName":"MelpDsMod","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2705096","version":"1","preferredName":"Melphalan Dose Clinical Trial Protocol Modification","preferredDefinition":"information related to the change, addition, or omission, as part of the action plan for a clinical trial, in the administered amount of melphalan, an orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity that alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","longName":"MEL_DOSE_PROT_MOD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2705062","version":"1","preferredName":"Melphalan Dose","preferredDefinition":"An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04):The amount of medicine taken, or radiation given, at one time.","longName":"C633:C25488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4061D6FE-169D-0FEE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-12-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-12-03","modifiedBy":"ONEDATA","dateModified":"2007-12-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2666439","version":"1","preferredName":"Clinical Trial Protocol Modification","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.:Modification; the act of making something different.","longName":"C25320:C25572","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Modification","conceptCode":"C25572","definition":"Modification; the act of making something different.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35B37B87-A0FA-34A3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-07-20","modifiedBy":"ONEDATA","dateModified":"2007-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4062D229-3FCE-2FC0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-12-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-12-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4132153","version":"1.1","preferredName":"Yes No Unable to Assess Indicator","preferredDefinition":"The preferred value domain to indicate a question with permissible values of yes/no/unable to assess.","longName":"YNUAssessIND","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unable to Assess","valueDescription":"Cannot Be Assessed","ValueMeaning":{"publicId":"2897789","version":"1","preferredName":"Cannot Be Assessed","longName":"2897789","preferredDefinition":"Aspects of the context prevent the evaluation needed to determine a value.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cannot Be Assessed","conceptCode":"C48657","definition":"Aspects of the context prevent the evaluation needed to determine a value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B943018-A5FF-1429-E040-BB89AD4312C2","latestVersionIndicator":"Yes","beginDate":"2009-06-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B949F6AF-F2EB-092F-E053-4EBD850AD67D","beginDate":"2021-01-19","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-01-19","modifiedBy":"ONEDATA","dateModified":"2021-01-19","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B949F802-E5C7-682D-E053-4EBD850AEBFC","beginDate":"2014-02-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-01-19","modifiedBy":"ONEDATA","dateModified":"2021-01-19","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3945562","version":"1","preferredName":"Yes","longName":"3945562","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA71051E-BFCC-9CF8-E040-BB89AD433955","latestVersionIndicator":"Yes","beginDate":"2013-11-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B949F802-E5D1-682D-E053-4EBD850AEBFC","beginDate":"2014-02-03","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-01-19","modifiedBy":"ONEDATA","dateModified":"2021-01-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B949F802-E5A6-682D-E053-4EBD850AEBFC","latestVersionIndicator":"Yes","beginDate":"2021-01-20","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2021-01-19","modifiedBy":"SPRINGERL","dateModified":"2021-01-20","changeDescription":"Fixed the concepts for Unable to Assess - LS 1/19/21","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Is there an anatomical abnormality involving the ophthalmic artery that will require increasing the dose of Melphalan for subsequent doses?","url":null,"context":"CTEP"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E41E2F31-52C3-5799-E053-731AD00A80D1","latestVersionIndicator":"Yes","beginDate":"2014-02-03","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-07-18","modifiedBy":"GDEEN","dateModified":"2022-07-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}